AlphaYou
Overview
Smart money at a glance
Filings to Oct 10, 2026Net selling: insiders sold $24M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$24M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 6 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 10- Open
- $18.13
- 52-wk high
- $19.85
- High
- $18.69
- 52-wk low
- $13.09
- Low
- $17.87
- Prev close
- $18.25
- Mkt cap
- $5.09B
- P/E
- 31.3x
- Volume
- 1.61M
- Fwd P/E
- 17.8x
- Beta
- 1.85
- P/S
- 4.2x
- P/B
- 7.8x
- Profit margin
- +13.4%
- Op margin
- +38.0%
- ROE
- +27.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about SHC filings
Are insiders buying or selling Sotera Health Co (SHC) stock?
Net selling: insiders sold $24M and bought $0 of SHC stock on the open market in the 90 days to Oct 10, 2026, according to SEC Form 4 filings. The largest was Petras, Michael B. Jr. (Executive Chairman), who sold $21.2M. The latest filing was on Aug 19, 2026.
Which members of Congress have traded SHC recently?
None. No member of Congress disclosed a SHC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this SHC smart-money data?
This summary uses filings available on Oct 10, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
What insiders are doing
Sells (3)
- PM
Petras Michael B. Jr.
$21.2M
sold
- RM
Rutz Michael P
$2.8M
sold
- WP
Warburg Pincus & Co.
$289.8M
sold
How top traders are positioned
No tracked top-trader positions in SHC right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 9.1% above what analysts expected.
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.22 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $0.24 / $0.22Alpha Vantage | +9.09% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.18 / $0.17Alpha Vantage | +5.88% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $0.26 / $0.24Alpha Vantage | +7.35% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $0.26 / $0.22Alpha Vantage | +18.18% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 8, 2025 | $0.20 / $0.17Alpha Vantage | +17.65% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $0.14 / $0.12Alpha Vantage | +16.67% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | $0.21 / $0.20Alpha Vantage | +4.01% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 5, 2024 | $0.17 / $0.18Alpha Vantage | -5.56% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 3, 2026, in 24 days
Estimates as of Oct 3, 2026
EPS expected
$0.26 to $0.27
Revenue expected
9 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $311.3M | $303.4M | $280.0M | $321.4M |
| Cost of what it sold | $133.8M | $137.5M | $136.0M | $143.4M |
| Gross profit | $177.6M | $165.9M | $144.0M | $178.0M |
| What it spent | ||||
| Sales and admin | $63.3M | $57.5M | $68.2M | $68.2M |
| Other operating costs | $3.1M | -$27.7M | -$10.8M | $3.0M |
| Total operating expenses | $66.4M | $29.8M | $57.4M | $71.2M |
| What was left | ||||
| Operating profit | $111.2M | $136.1M | $86.6M | $106.8M |
| Interest on debt | $39.1M | $35.0M | $34.7M | $34.4M |
| Profit before tax | $72.9M | $70.5M | $42.6M | $78.1M |
| Tax | $24.5M | $35.6M | $16.0M | $24.4M |
| Net profit | $48.4M | $34.8M | $26.6M | $53.6M |
| EBITDA | $140.4M | $138.1M | $108.2M | $145.9M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Transcript: Sotera Health Q2 2026 Earnings Conference Call
BullishOct 9Sotera Health Company (SHC) Stock forecasts
NeutralOct 9Sotera Health (SHC) Pullback Raises The Question As Undervaluation Claims Persist
Leans bullishOct 8Sotera Health stock carries Barclays Buy rating with USD 22 target
BullishOct 8Sotera Health stock gains 1.89 percent as Q2 growth supports outlook
BullishOct 5Analysts set USD 21.50 target for Sotera Health stock
BullishOct 2
Macro
20 macro signals shaping SHC right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results